With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.215798-19-9,6-Bromo-1,2,3,4-tetrahydroisoquinoline hydrochloride,as a common compound, the synthetic route is as follows.,215798-19-9
Triethylamine (2.8ml, 20 mmol) was added to a suspension of 6-bromo-1 ,2,3,4- tetrahydroisoquinoline hydrochloride (1g, 4.0 mmol, ASW MedChem Product List) and di-tert-butyl dicarbonate (1.87ml, 8.1 mmol) in methanol (10ml) at room temperature under nitrogen. The mixture was stirred overnight and then for a further 6h. The solvent was evaporated to give a white solid, which was partitioned between DCM and saturated sodium hydrogen carbonate solution, the organic dried (hydrophobic frit), and concentrated. The residue was dried under vacuum overnight, dissolved in methanol and applied to an SCX SPE (2Og). The cartridge was eluted with methanol and the fractions combined and evaporated to give 1 ,1- dimethylethyl 6-bromo-3,4-dihydro-2(1 H)-isoquinolinecarboxylate as a pale yellow gum (1.22g). LCMS (Method formate): Retention time 1.38min, MH+ = 312 / 314.
The synthetic route of 215798-19-9 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GLAXO GROUP LIMITED; BAILEY, James, Matthew; BIT, Rino, Antonio; DEMONT, Emmanuel, Hubert; HARRISON, Lee, Andrew; JONES, Katherine, Louise; SMETHURST, Christian, Alan, Paul; WITHERINGTON, Jason; WO2010/146105; (2010); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem